Country: India

Premas Biotech, based in Gurgaon, India, is a leading Contract Development and Manufacturing organization (CDMO) with 19 years of expertise. Specializing in protein delivery and therapeutic/vaccine development, Premas has successfully delivered over 750 proteins to more than 50 satisfied customers. Our partnerships span developed markets with multiple molecules in the clinical pipeline. Key Highlights: Quality and Compliance: Recognized as a DSIR “In-house Research & Development Unit” and ISO 9001:2015 certified by TUV SUD. Our GMP manufacturing facility is accredited by CDSCO (India) and audited by regulatory bodies from China, Israel, and the US FDA. We adhere strictly to SOPs, STPs, and maintain a robust Quality policy focused on high-quality product delivery. Customer-Centric Approach: Known for flexibility, on-time deliveries, cost reduction, and strong analytical development. We prioritize customer delight through continuous learning, integrity, ownership, and creativity. Process Excellence: Implementing lean manufacturing principles (Toyota Production System), we enhance efficiencies in project management and execution. Our scientific and project management strengths ensure successful process development and material supply for preclinical and clinical studies. Innovative Solutions: Expertise in expression and purification of proteins to meet IND filing specifications for biotherapeutic and vaccine candidates. We ensure robust scale-up, tech transfer, and clinical trial material supply using our GMP-compliant facility. Premas Biotech is committed to enabling quicker, more secure, and cost-effective therapeutic/vaccine development. We value interactive collaboration and welcome feedback to continuously improve our processes and outcomes. | Premas Biotech was founded with a singular mission: to enable the advancement of biologics by solving the challenge of producing difficult-to-express proteins. For over 20 years, Premas has built a differentiated capability stack across bacterial, yeast, and mammalian expression systems, supporting global partners from gene to clinic. Our integrated platform combines expression engineering, process development, analytical characterization, scale-up, and GMP manufacturing to accelerate timelines while reducing technical risk and cost of goods. At the core of Premas’ innovation engine is its proprietary D-Crypt™ platform, an engineered yeast-based system designed to express complex and membrane proteins that are traditionally intractable. This platform has enabled the successful delivery of 900+ proteins and multiple tech-transferred programs, positioning Premas as a strategic partner for next-generation biologics and vaccine development. We have expanded this foundation into a technology-driven vaccine development portfolio spanning recombinant antigens, virus-like particles (VLPs), circRNA-VLP constructs, and glycoconjugate carrier proteins. Our pipeline includes a first-in-class triple-antigen VLP vaccine candidate against SARS-CoV-2 that has completed Phase I clinical trials, alongside additional in-house programs targeting influenza, RSV, and other infectious diseases. With over 30 vaccine development programs executed across human and animal health, Premas delivers end-to-end, tech-transfer-ready solutions from design through GMP manufacturing. Complementing our biologics and vaccine platforms, we have developed AXTEX-4D™, a proprietary ex vivo 3D tissueoid platform that enables human-relevant disease modeling. Designed to better replicate in vivo tumor microenvironments, AXTEX-4D™ supports advanced applications across drug discovery, efficacy testing, and translational research, with compatibility across standard biological and analytical assays. By integrating protein engineering, platform-based vaccine development, and predictive human biology systems, we offer a unified, scalable engine to accelerate biologics innovation—bridging discovery, development, and clinical translation for global partners.